JP2016507502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507502A5 JP2016507502A5 JP2015549756A JP2015549756A JP2016507502A5 JP 2016507502 A5 JP2016507502 A5 JP 2016507502A5 JP 2015549756 A JP2015549756 A JP 2015549756A JP 2015549756 A JP2015549756 A JP 2015549756A JP 2016507502 A5 JP2016507502 A5 JP 2016507502A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- heterocyclyl
- carbocyclyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 121
- 125000000623 heterocyclic group Chemical group 0.000 claims 59
- 229910052799 carbon Inorganic materials 0.000 claims 43
- 229910052739 hydrogen Inorganic materials 0.000 claims 41
- 125000004452 carbocyclyl group Chemical group 0.000 claims 37
- 229910052760 oxygen Inorganic materials 0.000 claims 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 125000004432 carbon atom Chemical group C* 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims 3
- -1 CN Inorganic materials 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims 1
- 102000008122 Casein Kinase I Human genes 0.000 claims 1
- 108010049812 Casein Kinase I Proteins 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740564P | 2012-12-21 | 2012-12-21 | |
| US61/740,564 | 2012-12-21 | ||
| PCT/US2013/076795 WO2014100533A1 (en) | 2012-12-21 | 2013-12-20 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016507502A JP2016507502A (ja) | 2016-03-10 |
| JP2016507502A5 true JP2016507502A5 (https=) | 2017-01-12 |
| JP6267231B2 JP6267231B2 (ja) | 2018-01-24 |
Family
ID=49943572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549756A Expired - Fee Related JP6267231B2 (ja) | 2012-12-21 | 2013-12-20 | カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9556179B2 (https=) |
| EP (1) | EP2935271B1 (https=) |
| JP (1) | JP6267231B2 (https=) |
| CN (1) | CN105073751B (https=) |
| WO (1) | WO2014100533A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2935272B1 (en) | 2012-12-21 | 2017-02-22 | Bristol-Myers Squibb Company | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
| US9956220B2 (en) | 2014-06-19 | 2018-05-01 | Bristol-Myers Squibb Company | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors |
| EP3221318B1 (en) | 2014-11-21 | 2021-08-25 | Rigel Pharmaceuticals, Inc. | Fused imidazole derivatives as tgf-beta inhibitors |
| ES2789331T3 (es) * | 2015-03-02 | 2020-10-26 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
| CN107847480B (zh) | 2015-03-23 | 2021-06-25 | 墨尔本大学 | 呼吸性疾病的治疗 |
| CA2994027C (en) | 2015-07-31 | 2023-10-10 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
| NZ752196A (en) * | 2016-09-21 | 2022-05-27 | Vectus Biosystems Ltd | Compositions for the treatment of hypertension and/or fibrosis |
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| SI3774795T1 (sl) * | 2018-03-29 | 2022-07-29 | Masarykova Univerzita | 4-(1H-imidazol-5-il)-1H-pirolo (2,3-B) piridini za uporabo pri zdravljenju levkemij, limfomov in trdnih tumorjev |
| MX2021002652A (es) * | 2018-09-09 | 2021-09-23 | Qanatpharma Ag | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. |
| JP7575099B2 (ja) | 2018-11-07 | 2024-10-29 | ティアンリ バイオテック プロプライエタリ リミテッド | 呼吸器疾患の処理のための新規な化合物 |
| US11739078B2 (en) | 2019-02-22 | 2023-08-29 | Insilico Medicine Ip Limited | Methods of inhibiting kinases |
| CA3208490A1 (en) | 2021-02-24 | 2022-09-01 | Aleksandrs Zavoronkovs | Analogs for the treatment of disease |
| WO2025231112A1 (en) * | 2024-05-01 | 2025-11-06 | Nimbus Salacia, Inc. | Sik2 modulators and uses thereof |
| TW202547512A (zh) * | 2024-05-01 | 2025-12-16 | 美商林伯士薩拉西亞公司 | Sik2調節劑及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1532118A2 (en) * | 2002-07-05 | 2005-05-25 | Axxima Pharmaceuticals Aktiengesellschaft | Imidazole compounds for the treatment of hepatitis c virus infections |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20100029619A1 (en) | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
| WO2009005675A1 (en) * | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| AU2008343813B2 (en) | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
| WO2009137081A2 (en) | 2008-05-07 | 2009-11-12 | Massachusetts Institute Of Technology | Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| FR2940284B1 (fr) | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
| FR2940285A1 (fr) * | 2008-12-19 | 2010-06-25 | Sanofi Aventis | Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| SI2493876T1 (sl) | 2009-10-28 | 2014-04-30 | Pfizer Inc. | Derivati imidazola kot inhibitorji kazein-kinaze |
| EP2935272B1 (en) | 2012-12-21 | 2017-02-22 | Bristol-Myers Squibb Company | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
-
2013
- 2013-12-20 JP JP2015549756A patent/JP6267231B2/ja not_active Expired - Fee Related
- 2013-12-20 US US14/653,895 patent/US9556179B2/en active Active
- 2013-12-20 EP EP13818937.8A patent/EP2935271B1/en not_active Not-in-force
- 2013-12-20 WO PCT/US2013/076795 patent/WO2014100533A1/en not_active Ceased
- 2013-12-20 CN CN201380073382.4A patent/CN105073751B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016507502A5 (https=) | ||
| JP2016508135A5 (https=) | ||
| JP2017518344A5 (https=) | ||
| ES2925564T3 (es) | Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos | |
| AU2018358157B2 (en) | Modulators of the integrated stress pathway | |
| ES2266313T3 (es) | Derivados de triazolodiamina sustituidos como inhibidores de la quinasa. | |
| JP2016537366A5 (https=) | ||
| JP2016537369A5 (https=) | ||
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| CN109963854A (zh) | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2017507122A5 (https=) | ||
| JP2011525192A5 (https=) | ||
| CA3080808A1 (en) | Modulators of the integrated stress pathway | |
| JP2018522866A5 (https=) | ||
| JP2013528180A5 (https=) | ||
| JP2009542716A5 (https=) | ||
| JP2016503797A5 (https=) | ||
| JP2015503609A5 (https=) | ||
| JP2019535723A5 (https=) | ||
| JP2013542267A5 (https=) | ||
| JP2010527985A5 (https=) | ||
| JP2013518036A5 (https=) | ||
| JP2015522592A5 (https=) | ||
| ES2346323T3 (es) | Bencimidazoles sustituidos y su uso para inducir apoptosis. | |
| JP2014524449A5 (https=) |